Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

4 results
11:53 AM, Jul 13, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Assembly raises $144M follow-on

enter Phase I testing next quarter. Last year, Assembly licensed preclinical microbiome therapeutics ABI-M201 and ABI-M301
11:30 AM, Jul 12, 2018  |  BC Extra | Financial News

Assembly raises $144M follow-on

enter Phase I testing next quarter. Last year, Assembly licensed preclinical microbiome therapeutics ABI-M201 and ABI-M301
2:17 PM, Jan 12, 2017  |  BC Week In Review | Company News  |  Deals

Assembly, Allergan deal

exclusive, worldwide rights to preclinical candidates ABI-M201, which is in development for ulcerative colitis; and ABI-M301
will have an option to co-promote the programs in the U.S. and China. ABI-M201 and ABI-M301
4:30 PM, Jan 09, 2017  |  BC Extra | Company News

Allergan in deals with Lysosomal Therapeutics, Assembly

worldwide rights to preclinical microbiome therapeutics ABI-M201, which is in development for ulcerative colitis; and ABI-M301